CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Karyopharm - KPTI CFD

    0.65
    4.41%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.06
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Karyopharm Therapeutics Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 0.68
    Open* 0.68
    1-Year Change* -86.18%
    Day's Range* 0.65 - 0.7
    52 wk Range 0.67-5.42
    Average Volume (10 days) 782.49K
    Average Volume (3 months) 25.36M
    Market Cap 84.55M
    P/E Ratio -100.00K
    Shares Outstanding 114.53M
    Revenue 145.87M
    EPS -1.32
    Dividend (Yield %) N/A
    Beta -0.19
    Next Earnings Date Feb 13, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Nov 27, 2023 0.68 -0.02 -2.86% 0.70 0.73 0.68
    Nov 24, 2023 0.71 0.02 2.90% 0.69 0.77 0.69
    Nov 22, 2023 0.68 -0.04 -5.56% 0.72 0.72 0.68
    Nov 21, 2023 0.71 -0.02 -2.74% 0.73 0.77 0.71
    Nov 20, 2023 0.76 0.01 1.33% 0.75 0.79 0.74
    Nov 17, 2023 0.75 0.07 10.29% 0.68 0.76 0.68
    Nov 16, 2023 0.67 -0.04 -5.63% 0.71 0.73 0.67
    Nov 15, 2023 0.70 -0.05 -6.67% 0.75 0.77 0.70
    Nov 14, 2023 0.73 0.01 1.39% 0.72 0.76 0.71
    Nov 13, 2023 0.72 0.03 4.35% 0.69 0.73 0.66
    Nov 10, 2023 0.68 -0.01 -1.45% 0.69 0.70 0.65
    Nov 9, 2023 0.67 -0.06 -8.22% 0.73 0.74 0.65
    Nov 8, 2023 0.72 -0.05 -6.49% 0.77 0.77 0.71
    Nov 7, 2023 0.77 -0.09 -10.47% 0.86 0.86 0.77
    Nov 6, 2023 0.86 -0.05 -5.49% 0.91 0.94 0.86
    Nov 3, 2023 0.86 0.11 14.67% 0.75 0.88 0.75
    Nov 2, 2023 0.74 -0.04 -5.13% 0.78 0.82 0.72
    Nov 1, 2023 0.77 -0.08 -9.41% 0.85 0.85 0.76
    Oct 31, 2023 0.84 0.07 9.09% 0.77 0.86 0.77
    Oct 30, 2023 0.79 -0.03 -3.66% 0.82 0.87 0.79

    Karyopharm Events

    Time (UTC) Country Event
    Wednesday, November 29, 2023

    Time (UTC)

    21:00

    Country

    US

    Event

    Karyopharm Therapeutics Inc at Piper Sandler Healthcare Conference
    Karyopharm Therapeutics Inc at Piper Sandler Healthcare Conference

    Forecast

    -

    Previous

    -
    Tuesday, February 13, 2024

    Time (UTC)

    13:30

    Country

    US

    Event

    Q4 2023 Karyopharm Therapeutics Inc Earnings Release
    Q4 2023 Karyopharm Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 157.074 209.819 108.085 40.893 30.336
    Revenue 157.074 209.819 108.085 40.893 30.336
    Total Operating Expense 299.276 308.09 279.935 230.168 210.219
    Selling/General/Admin. Expenses, Total 145.401 143.846 126.417 105.421 48.847
    Research & Development 148.662 160.842 150.813 122.34 161.372
    Operating Income -142.202 -98.271 -171.85 -189.275 -179.883
    Interest Income (Expense), Net Non-Operating -22.637 -25.464 -24.32 -10.225 1.535
    Other, Net -0.083 -0.085 0.206 -0.05 -0.033
    Net Income Before Taxes -164.922 -123.82 -195.964 -199.55 -178.381
    Net Income After Taxes -165.291 -124.088 -196.273 -199.59 -178.407
    Net Income Before Extra. Items -165.291 -124.088 -196.273 -199.59 -178.407
    Net Income -165.291 -124.088 -196.273 -199.59 -178.407
    Income Available to Common Excl. Extra. Items -165.291 -124.088 -196.273 -199.59 -178.407
    Income Available to Common Incl. Extra. Items -165.291 -124.088 -196.273 -199.59 -178.407
    Diluted Net Income -165.291 -124.088 -196.273 -199.59 -178.407
    Diluted Weighted Average Shares 81.871 75.218 72.044 61.9554 56.7997
    Diluted EPS Excluding Extraordinary Items -2.01892 -1.64971 -2.72435 -3.22151 -3.14098
    Diluted Normalized EPS -2.01892 -1.64971 -2.72435 -3.22151 -3.14098
    Cost of Revenue, Total 5.213 3.402 2.705 2.407
    Gross Profit 151.861 206.417 105.38 38.486
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 37.579 38.698 33.58 36.145 39.679
    Revenue 37.579 38.698 33.58 36.145 39.679
    Cost of Revenue, Total 1.194 1.351 1.868 0.98 0.939
    Gross Profit 36.385 37.347 31.712 35.165 38.74
    Total Operating Expense 67.152 69.597 67.449 66.984 82.587
    Selling/General/Admin. Expenses, Total 34.481 35.907 34.649 34.645 37.339
    Research & Development 31.477 32.339 30.932 31.359 44.309
    Operating Income -29.573 -30.899 -33.869 -30.839 -42.908
    Interest Income (Expense), Net Non-Operating -2.96 -2.909 -4.551 -5.456 -6.02
    Other, Net 0.03 -0.264 -0.013 0.016 -0.013
    Net Income Before Taxes -32.503 -34.072 -38.433 -36.279 -48.941
    Net Income After Taxes -32.63 -34.126 -38.506 -36.324 -49.062
    Net Income Before Extra. Items -32.63 -34.126 -38.506 -36.324 -49.062
    Net Income -32.63 -34.126 -38.506 -36.324 -49.062
    Income Available to Common Excl. Extra. Items -32.63 -34.126 -38.506 -36.324 -49.062
    Income Available to Common Incl. Extra. Items -32.63 -34.126 -38.506 -36.324 -49.062
    Diluted Net Income -32.63 -34.126 -38.506 -36.324 -49.062
    Diluted Weighted Average Shares 114.207 113.481 90.025 80.21 79.651
    Diluted EPS Excluding Extraordinary Items -0.28571 -0.30072 -0.42773 -0.45286 -0.61596
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.28571 -0.30072 -0.42773 -0.45286 -0.61596
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 350.162 275.606 276.531 278.57 334.612
    Cash and Short Term Investments 277.967 228.615 249.24 261.956 328.199
    Cash & Equivalents 135.188 190.459 85.918 128.858 118.021
    Short Term Investments 142.779 38.156 163.322 133.098 210.178
    Prepaid Expenses 19.821 14.039 9.285 7.289 6.413
    Total Assets 358.172 305.305 313.05 294.963 341.192
    Property/Plant/Equipment, Total - Net 7.377 9.557 11.582 13.663 3.863
    Property/Plant/Equipment, Total - Gross 14.022 15.614 16.77 17.905 7.156
    Accumulated Depreciation, Total -6.645 -6.057 -5.188 -4.242 -3.293
    Long Term Investments 0 24.215 2.016 2.001
    Other Long Term Assets, Total 0.633 20.142 0.722 0.714 0.716
    Total Current Liabilities 65.908 73.718 60.203 46.35 46.904
    Accounts Payable 2.773 1.603 4.45 0.985 4.332
    Accrued Expenses 61.287 71.437 54.847 42.524 32.493
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 1.848 0.678 0.906 2.841 10.079
    Total Liabilities 374.828 384.978 262.504 245.189 158.022
    Total Long Term Debt 302.823 302.291 191.016 183.445 102.664
    Other Liabilities, Total 6.097 8.969 11.285 15.394 8.454
    Total Equity -16.656 -79.673 50.546 49.774 183.17
    Redeemable Preferred Stock 0 0 0 0 0
    Common Stock 0.012 0.008 0.007 0.007 0.006
    Additional Paid-In Capital 1327.91 1098.78 1119.63 923.142 857.156
    Retained Earnings (Accumulated Deficit) -1343.94 -1178.65 -1069.61 -873.338 -673.748
    Other Equity, Total -0.638 0.191 0.518 -0.037 -0.244
    Total Liabilities & Shareholders’ Equity 358.172 305.305 313.05 294.963 341.192
    Total Common Shares Outstanding 113.213 75.746 73.923 65.3705 60.8293
    Other Current Assets, Total 1.064 6.349 2.481 1.117 0
    Long Term Debt 302.823 302.291 191.016 183.445 102.664
    Total Receivables, Net 47.086 22.497 12.881 7.862
    Accounts Receivable - Trade, Net 47.086 22.497 12.881 7.862
    Total Inventory 4.224 4.106 2.644 0.346
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 263.222 291.381 318.541 350.162 222.677
    Cash and Short Term Investments 208.315 236.765 260.384 277.967 148.381
    Cash & Equivalents 43.655 80.894 84.062 135.188 71.351
    Short Term Investments 164.66 155.871 176.322 142.779 77.03
    Total Receivables, Net 37.923 32.28 35.2 47.086 27.446
    Accounts Receivable - Trade, Net 37.923 32.28 35.2 47.086 27.446
    Total Inventory 3.105 3.672 3.827 4.224 4.249
    Prepaid Expenses 13.334 18.097 18.284 19.821 41.521
    Other Current Assets, Total 0.545 0.567 0.846 1.064 1.08
    Total Assets 269.96 297.83 325.8 358.172 231.236
    Property/Plant/Equipment, Total - Net 5.482 6.062 6.625 7.377 7.933
    Long Term Investments
    Other Long Term Assets, Total 1.256 0.387 0.634 0.633 0.626
    Total Current Liabilities 62.079 58.928 61.555 65.908 61.761
    Accounts Payable 0.943 2.287 9.045 2.773 0.813
    Accrued Expenses 58.908 54.892 50.009 61.287 58.486
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 2.228 1.749 2.501 1.848 2.462
    Total Liabilities 370.356 369.078 370.974 374.828 371.516
    Total Long Term Debt 303.181 303.215 303.024 302.823 302.892
    Long Term Debt 303.181 303.215 303.024 302.823 302.892
    Other Liabilities, Total 5.096 6.935 6.395 6.097 6.863
    Total Equity -100.396 -71.248 -45.174 -16.656 -140.28
    Common Stock 0.012 0.012 0.012 0.012 0.008
    Additional Paid-In Capital 1345.54 1340.22 1333.3 1327.91 1165.9
    Retained Earnings (Accumulated Deficit) -1445.2 -1410.69 -1378.06 -1343.94 -1305.43
    Other Equity, Total -0.742 -0.783 -0.419 -0.638 -0.752
    Total Liabilities & Shareholders’ Equity 269.96 297.83 325.8 358.172 231.236
    Total Common Shares Outstanding 114.523 114.34 113.971 113.213 81.027
    Redeemable Preferred Stock 0 0 0 0 0
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -165.291 -124.088 -196.273 -199.59 -178.407
    Cash From Operating Activities -149.554 -107.116 -160.234 -190.822 -159.117
    Cash From Operating Activities 0.621 0.789 0.972 0.974 0.735
    Non-Cash Items 35.105 39.372 33.726 21.102 18.724
    Changes in Working Capital -19.989 -23.189 1.341 -13.308 -0.169
    Cash From Investing Activities -104.256 141.84 -53.685 78.45 -107.664
    Capital Expenditures -0.118 -0.212 -0.145 -0.206 -2.363
    Other Investing Cash Flow Items, Total -104.138 142.052 -53.54 78.656 -105.301
    Cash From Financing Activities 193.738 73.648 172.083 124.305 316.109
    Financing Cash Flow Items 0 60
    Issuance (Retirement) of Stock, Net 193.738 13.648 172.083 50.696 149.224
    Foreign Exchange Effects -0.488 -0.048 0.268 0.019 -0.078
    Net Change in Cash -60.56 108.324 -41.568 11.952 49.25
    Issuance (Retirement) of Debt, Net 0 73.609 166.885
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -34.126 -165.291 -126.785 -90.461 -41.399
    Cash From Operating Activities -18.91 -149.554 -122.711 -94.341 -59.197
    Cash From Operating Activities 0.29 0.621 0.508 0.326 0.177
    Non-Cash Items 4.468 35.105 29.464 22.754 7.577
    Changes in Working Capital 10.458 -19.989 -25.898 -26.96 -25.552
    Cash From Investing Activities -32.388 -104.256 -38.958 -50.631 -14.035
    Capital Expenditures 0 -0.118 -0.118 -0.079 -0.079
    Other Investing Cash Flow Items, Total -32.388 -104.138 -38.84 -50.552 -13.956
    Cash From Financing Activities 0 193.738 37.895 32.096 30.783
    Issuance (Retirement) of Stock, Net 0 193.738 37.895 32.096 30.783
    Foreign Exchange Effects -0.045 -0.488 -0.614 -0.544 -0.09
    Net Change in Cash -51.343 -60.56 -124.388 -113.42 -42.539
    Financing Cash Flow Items 0 0
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    BlackRock Institutional Trust Company, N.A. Investment Advisor 7.9037 9038183 2057417 2023-06-30 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 7.5805 8668620 1180292 2023-06-30 LOW
    Avidity Partners Management LP Hedge Fund 7.3194 8370100 -1263811 2023-06-30 HIGH
    Palo Alto Investors LP Hedge Fund 4.9634 5675876 0 2023-06-30 LOW
    Chione, Ltd. Corporation 3.8477 4400000 -600000 2022-12-31 LOW
    Citadel Advisors LLC Hedge Fund 2.7543 3149682 -452778 2023-06-30 LOW
    Marshall Wace LLP Investment Advisor/Hedge Fund 2.1372 2443997 459091 2023-06-30 HIGH
    ExodusPoint Capital Management, LP Hedge Fund 2.0834 2382451 2382451 2023-06-30 HIGH
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 1.9347 2212367 -7963622 2023-06-30 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.8688 2137094 365361 2023-06-30 LOW
    Opaleye Management Inc. Hedge Fund 1.5609 1785000 -1025800 2023-06-30 MED
    Delphi Ventures L.P. Venture Capital 1.5078 1724222 -538784 2023-03-20 LOW
    BlackRock Financial Management, Inc. Investment Advisor/Hedge Fund 1.3258 1516152 195001 2023-06-30 LOW
    C WorldWide Asset Management Fondsmaeglerselskab A/S Investment Advisor 1.3117 1500000 0 2023-06-30 LOW
    Candriam Belgium S.A. Investment Advisor/Hedge Fund 1.2555 1435694 -99332 2023-06-30 LOW
    AIGH Capital Management, LLC. Private Equity 1.1609 1327493 1327493 2023-06-30 MED
    Goldman Sachs & Company, Inc. Research Firm 1.089 1245318 -74332 2023-06-30 MED
    Millennium Management LLC Hedge Fund 1.0067 1151241 1137478 2023-06-30 HIGH
    Tejara Capital Ltd. Investment Advisor 1.0004 1143991 642429 2023-06-30 HIGH
    Candriam Luxembourg S.A. Investment Advisor 0.9975 1140630 -95000 2023-09-30 MED

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Karyopharm Company profile

    About Karyopharm Therapeutics Inc

    Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (CRM1). Its lead compound, XPOVIO (selinexor), is marketed in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). NEXPOVIO (selinexor), the brand name for XPOVIO in Europe, in combination with dexamethasone to treat adult patients with multiple myeloma. It is also developing treatments for other diseases.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Karyopharm Therapeutics Inc revenues increased 94% to $209.8M. Net loss decreased 37% to $124.1M. Revenues reflect License and other revenue increase from $31.9M to $111.4M, Product revenue, net increase of 29% to $98.4M. Lower net loss reflects Interest expense decrease of 4% to $26M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$2.72 to -$1.65.

    Equity composition

    Common Stock $0.0001 Par, 11/13, 100M auth., 28,729,593 issd. Insiders own approx. 76.33%

    Industry: Bio Therapeutic Drugs

    85 Wells Ave
    NEWTON CENTER
    MASSACHUSETTS 02459-3298
    US

    Income Statement

    • Annual
    • Quarterly

    News

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023
    GBP

    UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

    UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

    10:48, 21 November 2023

    Gold Rises as Traders price-in Fed Rate Cuts

    Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.

    13:17, 20 November 2023
    Gold bars

    XAU/USD Latest: Gold advances as weaker data weighs on US yields

    Gold moves higher as softer economic data weighs on US yields and the dollar

    13:43, 17 November 2023

    People also watch

    BTC/USD

    38,047.95 Price
    +2.710% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    XRP/USD

    0.62 Price
    +2.100% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    US100

    16,033.60 Price
    +0.450% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    Gold

    2,049.03 Price
    +1.730% 1D Chg, %
    Long position overnight fee -0.0192%
    Short position overnight fee 0.0110%
    Overnight fee time 22:00 (UTC)
    Spread 0.30

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading